Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, first-line trastuzumab deruxtecan (T-DXd; Enhertu) combined with pertuzumab ...

Dr. Joshua K. Sabari and Dr. Prantesh Jain delve into key lung cancer outcomes from the 2025 ASCO Meeting that patients should be aware of.

Small-cell lung cancer (SCLC) is one of the most lethal cancers, with patients diagnosed with extensive-stage small-cell lung cancer (ES-SCLC) experiencing a median survival of just 12 months after ...

Also contributing are women’s higher rates of thyroid cancer, and rising rates of cervix and uterus cancers. And while lung cancer rates are decreasing for everyone, they’re declining more ...

Scientists have discovered tumors can tap a nontraditional pathway to acquire lipoproteins—molecules that transport fat in ...

Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide with an estimated 2 million new cases and 1·76 million deaths per year. Substantial ...

A large Canadian study found that regular exercise after colon cancer treatment reduces the risk of cancer returning. Patients who followed a structured exercise program had higher survival rates ...

Xenoview is a hyperpolarized xenon inhaled contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation. The expanded approval increases patient ...

a rare event for a fatal brain cancer with few treatment options, researchers reported on Sunday. The study, presented at the American Society of Clinical Oncology meeting in Chicago and published ...

Perspective from Charu Aggarwal, MD, MPH, FASCO CHICAGO — A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from adjuvant ...